Connect Biopharma Holdings (CNTB) Interest Expenses (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Interest Expenses for 7 consecutive years, with $740000.0 the latest figure, recorded in Q1 2026.

• Quarterly Interest Expenses rose 873.68% year-over-year to $740000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $740000.0 (up 145.03% YoY) and the FY2025 annual result came in at $68.4 million, up 0.93% from the prior year.
• Interest Expenses improved to $740000.0 in Q1 2026 per CNTB's latest filing, from $131000.0 in the prior quarter.
• Over the last five years, Interest Expenses for CNTB reached as high as $64.4 million in Q4 2023 and fell as low as $20247.0 in Q4 2022.
• A 5-year average of $6.1 million and a median of $100000.0 in 2024 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 317799.15% — and 2024, when it plunged 99.88%.
• Year by year, Interest Expenses stood at $20247.0 in 2022, then jumped by 317799.15% to $64.4 million in 2023, then tumbled by 99.88% to $75000.0 in 2024, then jumped by 74.67% to $131000.0 in 2025, then jumped by 464.89% to $740000.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $740000.0, $131000.0, and $106000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.